690 results on '"Lambertini, M."'
Search Results
2. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
3. Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
4. The Future of Breast Cancer Research in the Survivorship Field
5. Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes
6. Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?
7. Pediatric oncofertility care in limited versus optimum resource settings: results from 39 surveyed centers in Repro-Can-OPEN Study Part I & II
8. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis
9. Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy
10. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis
11. Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology
12. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature
13. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
14. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group
15. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial
16. Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis
17. Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene
18. The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series
19. Installing oncofertility programs for breast cancer in limited versus optimum resource settings: Empirical data from 39 surveyed centers in Repro-Can-OPEN Study Part I & II
20. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer
21. The impact of synchronous liver resection on the risk of anastomotic leakage following elective colorectal resection. A propensity score match analysis on behalf of the iCral study group
22. Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
23. The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II
24. VISTA: A Promising Target for Cancer Immunotherapy?
25. The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration
26. Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network
27. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
28. CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
29. Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women
30. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†
31. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
32. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting
33. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
34. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients
35. Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis
36. Response to the letter entitled ‘On finding acceptance’
37. Re: Safety and efficacy concerns of long-acting GnRH agonist trigger for ovulation induction in oncological patients undergoing oocyte cryopreservation: a call for caution and further investigation
38. 228P The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: An exploratory analysis of the CLEOPATRA trial
39. 212P Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
40. 101P Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: An individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
41. 198P Relationship of diarrhea and neutropenia events with outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG): Post hoc analysis from the phase III ASCENT study
42. 276P Safety of pregnancy after early breast cancer in young women with hormone receptor-positive disease: A systematic review and meta-analysis
43. 108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study)
44. 35P SNPs of aromatase gene (CYP19A1) and outcomes of patients with estrogen receptor-positive (ER+) early breast cancer (eBC) treated with aromatase inhibitors (AIs): A multicenter, prospective study
45. 429P Brain imaging screening (BIS) in metastatic breast cancer (MBC): Patients’ and physicians’ perspectives
46. 357P Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC)
47. 338TiP EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
48. 302P Perceptions of women with HER2+ breast cancer on the risk of recurrence and disease management: Results from the ASKHER survey
49. 290P Subtype-specific prognostic value of lobular histology in patients with early-stage breast cancer: A nationwide population-based study
50. 269P Her2-low/HRR proficient early triple negative breast cancer is characterized by good prognosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.